How India Exports Nivolumab to the World

Nivolumab, a monoclonal antibody targeting PD-1, is approved in the United States under the brand name Opdivo. As of March 2026, the FDA Orange Book lists no approved Abbreviated New Drug Applications (ANDAs) for Nivolumab, indicating the absence of generic competition in the U.S. market. The original Biologics License Application (BLA) for Opdivo was approved in December 2014. Subsequent approvals have expanded its indications, including a notable approval in June 2025 for the treatment of esophageal squamous cell carcinoma.

Given the absence of ANDAs, Indian exporters face significant regulatory hurdles in entering the U.S. market with Nivolumab. The Biologics Price Competition and Innovation Act (BPCIA) outlines the pathway for biosimilar approval, requiring comprehensive analytical, preclinical, and clinical data to demonstrate biosimilarity to the reference product. Additionally, the FDA's import alert database, as of March 2026, does not list any import alerts specific to Nivolumab, suggesting no current compliance issues for this product.

In the European Union, Nivolumab received marketing authorization from the European Medicines Agency (EMA) in July 2015 under the brand name Opdivo. The authorization has been updated to include additional indications, with the most recent expansion in September 2025 for the treatment of gastric cancer. The United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) granted a corresponding authorization in October 2015, with similar subsequent updates.

Manufacturers exporting Nivolumab to the EU and UK must comply with Good Manufacturing Practice (GMP) standards as outlined in EU Directive 2003/94/EC. These standards ensure product quality and safety, requiring regular inspections and adherence to stringent manufacturing protocols.

Nivolumab is included in the 22nd edition of the WHO Model List of Essential Medicines, published in July 2021, recognizing its significance in cancer treatment. However, as of March 2026, Nivolumab has not been prequalified by the WHO Prequalification Programme, which primarily focuses on medicines for HIV, malaria, tuberculosis, and reproductive health.

Regarding pharmacopoeial standards, Nivolumab is listed in the United States Pharmacopeia (USP) as of the 2024 edition. It is not currently included in the British Pharmacopoeia (BP), European Pharmacopoeia (EP), or Indian Pharmacopoeia (IP).

In India, Nivolumab is classified as a Schedule H drug under the Drugs and Cosmetics Act, requiring a prescription for dispensing. The National Pharmaceutical Pricing Authority (NPPA) has not set a ceiling price for Nivolumab as of March 2026, allowing market-driven pricing. For export purposes, the Directorate General of Foreign Trade (DGFT) mandates a No Objection Certificate (NOC) for the export of Nivolumab, ensuring compliance with national regulations.

Nivolumab's primary patent in India expired in December 2024, opening the market to potential generic competition. However, the complexity of biologic manufacturing and the stringent regulatory requirements for biosimilars have limited the entry of generic versions into the market as of March 2026.

In May 2025, the Indian Ministry of Health and Family Welfare revised the guidelines for biosimilar approval, streamlining the process to encourage domestic production of complex biologics like Nivolumab. This policy change aims to enhance the availability of affordable cancer treatments.

In August 2025, the NPPA initiated a review of pricing policies for high-cost biologics, including Nivolumab, to assess the need for potential price controls. The outcome of this review is pending as of March 2026.

In November 2025, the Central Drugs Standard Control Organization (CDSCO) approved the first Indian-manufactured biosimilar of Nivolumab, marking a significant milestone in the domestic production of complex biologics.

In January 2026, the World Health Organization (WHO) updated its guidelines on biosimilar evaluation, emphasizing the need for robust clinical data to demonstrate similarity to reference products. This update impacts regulatory strategies for Nivolumab biosimilars globally.

In February 2026, the Indian government announced incentives for pharmaceutical companies investing in the development and manufacturing of biosimilars, including Nivolumab, to bolster the country's position in the global biologics market.

The production of Nivolumab relies on complex biotechnological processes involving specific Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs). Historically, India has depended heavily on imports for these critical components, particularly from China, which controls a significant portion of the global KSM supply. This dependency poses a strategic risk, as any disruption in the supply chain can lead to production halts and subsequent shortages.

To mitigate this risk, the Indian government has implemented the Production Linked Incentive (PLI) Scheme for Bulk Drugs, aiming to promote domestic manufacturing of critical KSMs, DIs, and APIs. As of September 2025, the scheme has led to the creation of domestic manufacturing capacity for 26 KSMs/APIs, resulting in cumulative sales of ₹2,315 crore and avoiding imports worth ₹1,807 crore. This initiative is a significant step towards reducing reliance on imports and enhancing supply chain resilience.

The export market for Nivolumab from India is moderately concentrated, with the top five exporters accounting for 36.0% of the total export value. DR. REDDY'S LABORATORIES LTD holds the largest share at 25.3%, followed by smaller contributions from other exporters. This concentration indicates a potential risk, as disruptions affecting major suppliers could significantly impact the availability of Nivolumab in international markets.

The PLI Scheme for Bulk Drugs has been instrumental in encouraging diversification among manufacturers. By September 2025, the scheme had attracted investments exceeding initial commitments, with ₹4,570 crore invested against a commitment of ₹3,938.5 crore over six years. This has led to the establishment of new manufacturing units, thereby reducing single-source dependency and enhancing the robustness of the supply chain.

Global shipping routes, including the Red Sea and the Strait of Hormuz, are critical for the transportation of pharmaceutical products. Any geopolitical tensions or conflicts in these regions can lead to shipping delays, increased costs, and potential shortages. Additionally, ongoing US-China trade tensions have prompted countries to reassess their supply chain dependencies, particularly concerning APIs and KSMs.

Regulatory bodies such as the FDA and EMA have issued alerts regarding drug shortages, often attributing them to supply chain disruptions. These shortages underscore the importance of a diversified and resilient supply chain to ensure the uninterrupted availability of essential medications like Nivolumab.

• Diversify Supplier Base: Encourage the development of multiple suppliers for Nivolumab and its components to reduce reliance on a limited number of exporters.

• Enhance Domestic Production: Continue to support and expand initiatives like the PLI Scheme to bolster domestic manufacturing of APIs and KSMs, thereby reducing import dependency.

• Monitor Geopolitical Developments: Establish a dedicated team to track geopolitical events that could impact shipping routes and supply chains, enabling proactive risk management.

• Strengthen Regulatory Compliance: Ensure that all suppliers adhere to international quality standards to prevent regulatory actions that could disrupt supply.

• Develop Contingency Plans: Create comprehensive contingency strategies to address potential supply chain disruptions, including alternative sourcing and logistics solutions.

RISK_LEVEL: MEDIUM